Get Full Regulatory Alignment Or See Post-Brexit Declines In Trials, Manufacturing, Product Launches, Says UK Committee

Stakeholders that gave evidence to a UK parliamentary inquiry into the impact of Brexit on medicines and medical devices said full regulatory alignment was vital if the UK was to avoid declines in clinical trial and manufacturing activity and delays in the launch of new drugs.